# Cambridge Cancer Genomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cambridge-cancer-genomics

- Industry: Software
- Headquarters: Cambridge, UK
- Website: www.ccg.ai
- Total disclosed funding: $4.5M
- Latest round: Seed (Dec 1, 2018)
- Investors on record: 5

## About

Cambridge Cancer Genomics Limited is a pioneering company focused on revolutionizing cancer care through innovative genomic data solutions. Their platform aids in enhancing patient treatment outcomes using advanced analytics and AI technologies.Cambridge Cancer Genomics Limited, founded in 2016 in Cambridge, UK, specializes in leveraging genomic data for cancer care improvement. In June 2021, the company was acquired by Dante Genomics, enabling further integration into clinical oncology solutions. The company has completed 2 deals, with its latest funding round being a Seed round in which it raised USD 4.5 mn from investors including AME Cloud Ventures and Y Combinator. The total amount raised by the company stands at USD 4.5 mn.CCG.ai specializes in providing a comprehensive marketplace for domain names, focusing on expert-curated, brandable options aimed at enhancing business visibility and identity. Their core offerings include access to over 300,000 premium domains, including one-word domains with modern extensions such as .ai, .io, and .xyz. These domains cater to various client needs, helping businesses establish a unique online presence. Additionally, CCG.ai offers services such as naming contests facilitated by branding experts, AI-powered name and logo generation tools, trademark services, and data-driven survey capabilities for informed decision-making. The company targets a global market, reaching startups, established businesses, and entrepreneurs across diverse geographical regions including the United States, Europe, and Asia.CCG.ai generates revenue through the sale of domain names and associated branding services. Business transactions typically occur via direct sales where clients can purchase domains instantly through the Atom.com marketplace, designed for seamless transactions. The company offers a range of pricing plans, enhancing accessibility for various business sizes. Furthermore, CCG.ai promotes partnerships with clients through comprehensive branding solutions, which may include logo design and trademark assistance, fostering long-term relationships. The transaction structure primarily reflects a direct-to-consumer model, enabling businesses to acquire the necessary digital assets and services to thrive in a competitive market.Following its recent acquisition on June 23, 2021, by Dante Genomics, the company will leverage the funding to develop innovative oncology solutions and expand its market presence. The integration aims to enhance capabilities in providing clinical organizations with comprehensive oncology solutions. This acquisition facilitates reaching a broader range of clinical organizations, supporting strategies to improve patient outcomes in cancer treatment.

## Funding rounds

- Seed, Dec 1, 2018, $4.5M — Romulus Capital, Y Combinator, AME Cloud Ventures, Refactor Capital, Comprehensive Blood & Cancer Center

## Investors

- Romulus Capital — Seed
- Y Combinator (https://capitalatlas.ai/funds/y-combinator) — Seed
- AME Cloud Ventures (https://capitalatlas.ai/funds/ame-cloud-ventures) — Seed
- Refactor Capital (https://capitalatlas.ai/funds/refactor-capital) — Seed
- Comprehensive Blood & Cancer Center — Seed